BPCR
NEUTRALBioPharma Credit PLC Provides Updates on Investments
The investment trust provides updates on partial prepayment from BioCryst Pharmaceuticals and additional investment commitment to Evolus, Inc.
BioPharma Credit
0.8820USD
0.92%
Market Cap
996.07M
Volume
2.1k
0% of avg
P/E Ratio
EPS (TTM)
Beta
0.1
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.8820p0.9400p
0.8820p
Upcoming Events
BPCR
NEUTRALBioPharma Credit Announces Change in Major Shareholding
The asset manager Adage Capital Management has reduced its stake in the investment trust BioPharma Credit PLC.
BPCR
NEUTRALBioPharma Credit Receives $8.25M Settlement from Biogen
The life sciences debt investor has received a settlement payment from Biogen, resolving a dispute over a loan agreement.
BPCR
NEUTRALBioPharma Credit PLC Announces Director Dealings
The major biopharmaceutical investment company has announced changes to its major shareholdings.
BPCR
NEUTRALBioPharma Credit Appoints Investec as Joint Corporate Broker
The life sciences debt investor has appointed Investec Bank plc as a joint corporate broker alongside JPMorgan Cazenove.
BPCR
NEUTRALBioPharma Credit PLC Announces Director Dealings
The major shareholder Adage Capital Management L.P. has reduced its stake in the biopharmaceutical investment company.
BPCR
NEUTRALBioPharma Credit PLC Announces Director Shareholding Transaction
The retailer has announced a director's personal shareholding transaction, with no further details provided.
BPCR
NEUTRALBioPharma Credit PLC Announces Change in Major Shareholding
The asset management firm has increased its stake in the investment trust, which primarily invests in interest-bearing debt assets secured by royalties or other cash flows from approved life sciences products.
BPCR
NEUTRALBioPharma Credit PLC Announces Full Year Results Release Date
The specialist life sciences debt investor will announce its full year results on 25 March 2025.